Current and future intratumoral targeted treatment for pancreatic cancer

Therapeutic Delivery

Volumn 5, Issue 8, 2014, Pages 913-926

  Zarogoulidis, Paul ^a   Pavlioglou, Paschalis ^b   Pivert, Patrick Le ^c   Machairiotis, Nikolaos ^d   Katsikogiannis, Nikolaos ^d   Kougioumtzi, Ioanna ^d   Tsimogiannis, Konstantinos ^e   Kakolyris, Stylianos ^d   Courcoutsakis, Nikolaos ^d   Tsiouda, Theodora ^f   Sakkas, Antonios ^a   Makrantonaki, Dimitra ^f   Zarogoulidis, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Theageneio Anticancer Hospital of Thessaloniki   (Greece)

^c Interventional Drug Delivery Systems and Strategies (ID2S2)   (United States)

^d UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^e G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^f Cancer Hospital Theagenio   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRCA2 PROTEIN; CHEMOKINE RECEPTOR CXCR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NEUROTENSIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN P16; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RAS PROTEIN; SMAD4 PROTEIN; VASCULOTROPIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; STK11 PROTEIN, HUMAN; VASCULOTROPIN A;

ANTINEOPLASTIC ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; GENE THERAPY; LYMPH NODE; NONHUMAN; PALLIATIVE THERAPY; PANCREAS CANCER; REVIEW; ANTAGONISTS AND INHIBITORS; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; TUMOR SUPPRESSOR GENE;

GENES, P16; HUMANS; MOLECULAR TARGETED THERAPY; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908332469     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.44     Document Type: Review

References (156)

1. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study. Br. J. Surg 82(1), 111-115 (1995).
2. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am. J. Surg. 165(1), 68-72 (1993). discussion 72-63
3. Yin Q, Wang C, Wu Z et al. Adenosquamous carcinoma of the pancreas: Multidetector-row computed tomographic manifestations and tumor characteristics. J. Comput. Assist Tomogr. 37(2), 125-133 (2013).
4. Marion-Audibert AM, Barel C, Gouysse G et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 125(4), 1094-1104 (2003).
5. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J. Cell. Sci. 113(Pt 22), 3897-3905 (2000).
6. Lee KT, Lee YW, Lee JK et al. Overexpression of Id-1 is significantly associated with tumour angiogenesis in human pancreas cancers. Br. J. Cancer. 90(6), 1198-1203 (2004).
7. Rubbia-Brandt L, Terris B, Giostra E, Dousset B, Morel P, Pepper MS. Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clin. Cancer Res. 10(20), 6919-6928 (2004).
8. Weekes CD, Song D, Arcaroli J et al. Stromal cell-derived factor 1alpha mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia 14(8), 690-701 (2012).
9. Schneider M, Buchler P, Giese N et al. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. Int. J. Oncol. 28(4), 883-890 (2006).
10. Nakamura T, Kuwai T, Kim JS, Fan D, Kim SJ, Fidler IJ. Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Neoplasia 9(11), 979-986 (2007).
11. Kapoor S. Tea consumption and the risk for pancreatic cancer. Pancreas 38(5), 593; (2009). Author reply 593-594
12. Kilian M, Mautsch I, Gregor JI et al. Influence of conjugated and conventional linoleic acid on tumor growth and lipid peroxidation in pancreatic adenocarcinoma in hamster. Prostaglandins Leukot. Essent. Fatty Acids 69(1), 67-72 (2003).
13. Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer-The role of pharmacogenetics. Curr. Drug Targets 13(6), 811-828 (2012).
14. Abraham J, Earl HM, Pharoah PD, Caldas C. Pharmacogenetics of cancer chemotherapy. Biochim. Biophys. Acta 1766(2), 168-183 (2006).
15. Kang SP, Saif MW. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP 9(3), 251-266 (2008).
16. Murphy BA. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J. Support Oncol. 5(9 Suppl 4), 13-21 (2007).
17. Cesarman-Maus G, Meillon L, Volkow P et al. [Treatment of cancer and thrombosis: Practical approach]. Rev. Invest. Clin. 65(2), 174-182 (2013).
18. Mortenson MM, Galante JG, Gilad O et al. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J. Cell Biochem. 102(5), 1171-1179 (2007).
19. Hasegawa N, Abei M, Yokoyama KK et al. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters. Int. J. Cancer 133(6), 1479-1488 (2013).
20. Hase R, Miyamoto M, Uehara H et al. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice. Clin. Cancer Res. 11(24 Pt 1), 8737-8744 (2005).
21. Horev-Drori G, Cooks T, Bittan H et al. Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224 radium-loaded wires releasing alpha-emitting atoms. Transl. Res. 159(1), 32-41 (2012).
22. Hecht JR, Farrell JJ, Senzer N et al. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: A phase I/II study. Gastrointest. Endosc. 75(2), 332-338 (2012).
23. Offit K, Bradbury A, Storm C, Merz JF, Noonan KE, Spence R. Gene patents and personalized cancer care: Impact of the myriad case on clinical oncology. J. Clin. Oncol. 31(21), 2743-2748 (2013).
24. Potter MA, Chang PL. Review-The use of immunosuppressive agents to prevent neutralizing antibodies against a transgene product. Ann. N. Y. Acad. Sci. 875, 159-174 (1999).
25. Hofmann M, Pflanzer R, Zoller NN et al. Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor. Transl. Oncol. 6(4), 398-404 (2013).
26. Willis AL, Sabeh F, Li XY, Weiss SJ. Extracellular matrix determinants and the regulation of cancer cell invasion stratagems. J. Microsc 251(3), 250-260 (2013).
27. Chiu CL, Digman MA, Gratton E. Cell matrix remodeling ability shown by image spatial correlation. J. Biophys.532030, (2013). (2013).
28. Bae YH. Interview with Dr. You Han Bae: Ligand-mediated versus 'passive' targeting approaches in nanoparticle oncology research. Ther. Deliv. 3(8), 933-936 (2012).
29. Sim H, Bibee K, Wickline S, Sept D. Pharmacokinetic modeling of tumor bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapy. Cancer Res. 71(3), 686-692 (2011).
30. Li C, Wang Y, Zhang X, Deng L, Zhang Y, Chen Z. Tumor-Targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide. Int. J. Nanomedicine 8, 1051-1062 (2013).
31. Liesveld J, Asselin B. It's ALL in the liposomes: Vincristine gets a new package. J. Clin. Oncol. 31(6), 657-659 (2013).
32. Zhao W, Zhuang S, Qi XR. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int. J. Nanomedicine 6, 3087-3098 (2011).
33. Jia Y, Yuan M, Yuan H et al. Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery. Int. J. Nanomedicine 7, 1697-1708 (2012).
34. De Snoo FA, Bishop DT, Bergman W et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin. Cancer Res. 14(21), 7151-7157 (2008).
35. Guweidhi A, Kleeff J, Giese N et al. Enhanced expression of 14-13-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis 25(9), 1575-1585 (2004).
36. Hustinx SR, Hruban RH, Leoni LM et al. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: A potential new target for therapy. Cancer Biol. Ther. 4(1), 83-86 (2005).
37. Bournet B, Dufresne M, Selves J, Torrisani J, Cordelier P, Buscail L. Kras oncogene and pancreatic cancer: Thirty years after. Med. Sci. (Paris) 29(11), 991-997 (2013).
38. Shi C, Fukushima N, Abe T et al. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol. Ther. 7(3), 353-360 (2008).
39. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 58(23), 5329-5332 (1998).
40. Dumont N, Arteaga CL. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3(6), 531-536 (2003).
41. Yang YA, Dukhanina O, Tang B et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109(12), 1607-1615 (2002).
42. Muraoka RS, Dumont N, Ritter CA et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109(12), 1551-1559 (2002).
43. Callahan JF, Burgess JL, Fornwald JA et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J. Med. Chem. 45(5), 999-1001 (2002).
44. Inman GJ, Nicolas FJ, Callahan JF et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62(1), 65-74 (2002).
45. Laping NJ, Grygielko E, Mathur A et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol. Pharmacol. 62(1), 58-64 (2002).
46. Wilentz RE, Su GH, Dai JL et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : A new marker of DPC4 inactivation. Am. J. Pathol. 156(1), 37-43 (2000).
47. Blackford A, Serrano OK, Wolfgang CL et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin. Cancer Res. 15(14), 4674-4679 (2009).
48. Peng B, Fleming JB, Breslin T et al. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. Clin. Cancer Res. 8(11), 3628-3638 (2002).
49. Ishiguro Y, Ishiguro H, Miyamoto H. Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia. Oncotarget 4(4), 550-559 (2013).
50. Turkson J, Ryan D, Kim JS et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276(48), 45443-45455 (2001).
51. Ren Z, Cabell LA, Schaefer TS, Mcmurray JS. Identification of a high-Affinity phosphopeptide inhibitor of Stat3. Bioorg. Med. Chem. Lett. 13(4), 633-636 (2003).
52. Turkson J, Kim JS, Zhang S et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. 3(3), 261-269 (2004).
53. Siddiquee KA, Gunning PT, Glenn M et al. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem. Biol. 2(12), 787-798 (2007).
54. Chen J, Bai L, Bernard D et al. Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. ACS Med. Chem. Lett. 1(2), 85-89 (2010).
55. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: A small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13(11), 1235-1242 (2006).
56. Chen CL, Loy A, Cen L et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 7, 111 (2007).
57. Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. USA 102(13), 4700-4705 (2005).
58. Mencalha AL, Du Rocher B, Salles D, Binato R, Abdelhay E. LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. Cancer Chemother. Pharmacol. 65(6), 1039-1046 (2010).
59. Ball S, Li C, Li PK, Lin J. The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One 6(4), e18820 (2011).
60. Liu A, Liu Y, Jin Z et al. XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS One 7(10), e46624 (2012).
61. Siddiquee K, Zhang S, Guida WC et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. USA 104(18), 7391-7396 (2007).
62. Fletcher S, Singh J, Zhang X et al. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: Potent in vitro and tumor cell activities. Chembiochem 10(12), 1959-1964 (2009).
63. Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, Turkson J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem. Pharmacol. 79(10), 1398-1409 (2010).
64. Shin DS, Kim HN, Shin KD et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 69(1), 193-202 (2009).
65. Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D. STAT inhibitors for cancer therapy. J. Hematol. Oncol. 6, 90 (2013).
66. Gaspar NJ, Li L, Kapoun AM et al. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol. Pharmacol. 72(1), 152-161 (2007).
67. Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin. Cancer Res. 13(14), 4233-4244 (2007).
68. Sato N, Rosty C, Jansen M et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am. J. Pathol. 159(6), 2017-2022 (2001).
69. Morton JP, Jamieson NB, Karim SA et al. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 139(2), 586-597 597 e581-e586 (2010).
70. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One 4(3), e4771 (2009).
71. Korsse SE, Peppelenbosch MP, Van Veelen W. Targeting LKB1 signaling in cancer. Biochim. Biophys. Acta 1835(2), 194-210 (2013).
72. Haigis KM, Kendall KR, Wang Y et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40(5), 600-608 (2008).
73. Goggins M, Schutte M, Lu J et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56(23), 5360-5364 (1996).
74. Mijatovic T, Gailly P, Mathieu V et al. Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration. Cell. Oncol. 29(4), 315-326 (2007).
75. Yamada N, Hamada T, Goto M et al. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int. J. Cancer 119(8), 1850-1857 (2006).
76. Fauquette V, Aubert S, Groux-Degroote S et al. Transcription factor AP-2alpha represses both the mucin MUC4 expression and pancreatic cancer cell proliferation. Carcinogenesis 28(11), 2305-2312 (2007).
77. Jones S, Hruban RH, Kamiyama M et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324(5924), 217 (2009).
78. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007).
79. Yamamoto S, Tomita Y, Hoshida Y et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 10(8), 2846-2850 (2004).
80. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23(53), 8571-8580 (2004).
81. Perugini RA, Mcdade TP, Vittimberga FJ Jr, Callery MP. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J. Surg. Res. 90(1), 39-44 (2000).
82. Lu X, Qian J, Yu Y, Yang H, Li J. Expression of the tumor suppressor ARHI inhibits the growth of pancreatic cancer cells by inducing G1 cell cycle arrest. Oncol. Rep. 22(3), 635-640 (2009).
83. Roy SK, Srivastava RK, Shankar S. Inhibition of PI3K/ AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J. Mol. Signal. 5, 10 (2010).
84. Ma J, Sawai H, Ochi N et al. PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol. Cell. Biochem. 331(1-2), 161-171 (2009).
85. Yao Z, Okabayashi Y, Yutsudo Y, Kitamura T, Ogawa W, Kasuga M. Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. Pancreas 24(1), 42-46 (2002).
86. Ripka S, Neesse A, Riedel J et al. CUX1: Target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut 59(8), 1101-1110 (2010).
87. Maitra A, Hruban RH. A new mouse model of pancreatic cancer: PTEN gets its Akt together. Cancer Cell 8(3), 171-172 (2005).
88. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS Jr, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol. Cell. Biol. 20(5), 1626-1638 (2000).
89. Reddy SA, Huang JH, Liao WS. Phosphatidylinositol 3-kinase as a mediator of TNF-induced NF-kappa B activation. J. Immunol. 164(3), 1355-1363 (2000).
90. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21(2), 81-86 (1998).
91. Birnbaum DJ, Adelaide J, Mamessier E et al. Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer 50(6), 456-465 (2011).
92. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23(31), 8033-8040 (2005).
93. Van Buren G 2nd, Ramanathan RK, Krasinskas AM et al. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann. Surg. Oncol. (2013).
94. Kindler HL, Niedwiecki D, Hollis D et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). ASCO ((2007)).
95. Raatschen HJ, Fischer S, Zsivcsec B et al. Non-invasive quantification of anti-Angiogenic therapy by contrast-enhanced MRI in experimental pancreatic cancer. Acta Radiol. (2013).
96. Lambrechts D, Claes B, Delmar P et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 13(7), 724-733 (2012).
97. Koshiba T, Hosotani R, Miyamoto Y et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression. Clin. Cancer Res. 6(9), 3530-3535 (2000).
98. Marchesi F, Monti P, Leone BE et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 64(22), 8420-8427 (2004).
99. Mori T, Doi R, Koizumi M et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol. Cancer Ther. 3(1), 29-37 (2004).
100. Saur D, Seidler B, Schneider G et al. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology 129(4), 1237-1250 (2005).
101. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20(11), 1915-1924 (2006).
102. Thomas RM, Kim J, Revelo-Penafiel MP, Angel R, Dawson DW, Lowy AM. The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia. Gut 57(11), 1555-1560 (2008).
103. Shen X, Artinyan A, Jackson D, Thomas RM, Lowy AM, Kim J. Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways. Pancreas 39(1), 81-87 (2010).
104. Maitra A, Ashfaq R, Gunn CR et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: An immunohistochemical analysis with automated cellular imaging. Am. J. Clin. Pathol. 118(2), 194-201 (2002).
105. Ma JX, Sun YL, Wang YQ, Wu HY, Jin J, Yu XF. Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF. Oncol. Res. 20(8), 359-368 (2013).
106. Shen X, Han L, Ma Z et al. Aspirin: A potential therapeutic approach in pancreatic cancer. Curr. Med. Chem.(2013).
107. Trevino JG, Summy JM, Lesslie DP et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. 168(3), 962-972 (2006).
108. Henke RT, Haddad BR, Kim SE et al. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin. Cancer Res. 10(18 Pt 1), 6134-6142 (2004).
109. Dehm SM, Bonham K. SRC gene expression in human cancer: The role of transcriptional activation. Biochem. Cell. Biol. 82(2), 263-274 (2004).
110. Nobis M, Mcghee EJ, Morton JP et al. Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of Src in pancreatic cancer. Cancer Res.73(15), 4674-4686 (2013).
111. Wharry CE, Haines KM, Carroll RG, May MJ. Constitutive non-canonical NFkappaB signaling in pancreatic cancer cells. Cancer Biol. Ther. 8(16), 1567-1576 (2009).
112. Yu G, Wan R, Hu Y et al. Pancreatic acinar cells-derived cyclophilin A promotes pancreatic damage by activating NF-kappaB pathway in experimental pancreatitis. Biochem. Biophys. Res. Commun. 444(1), 75-80 (2014).
113. Liou GY, Doppler H, Necela B et al. Macrophage-secreted cytokines drive pancreatic acinar-To-ductal metaplasia through NF-kappaB and MMPs. J. Cell. Biol. 202(3), 563-577 (2013).
114. Ortis F, Miani M, Colli ML et al. Differential usage of NF-kappaB activating signals by IL-1beta and TNF-Alpha in pancreatic beta cells. FEBS Lett. 586(7), 984-989 (2012).
115. Magne N, Toillon RA, Bottero V et al. NF-kappaB modulation and ionizing radiation: Mechanisms and future directions for cancer treatment. Cancer Lett.231(2), 158-168 (2006).
116. Shamoto T, Matsuo Y, Shibata T et al. Zerumbone inhibits angiogenesis by blocking NF-kappaB activity in pancreatic cancer. Pancreas 43(3), 396-404 (2014).
117. Bimonte S, Barbieri A, Palma G, Luciano A, Rea D, Arra C. Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer. Biomed. Res. Int. 810423 (2013).
118. Kim SO, Kim MR. [6]-Gingerol prevents disassembly of cell junctions and activities of MMPs in Invasive Human Pancreas Cancer Cells through ERK/NF-kappa B/Snail signal transduction pathway. Evid. Based Complement Alternat. Med. 761852 (2013).(2013).
119. Brandi G, Tavolari S, Guarnieri T et al. Antiprotease strategy in pancreatic cancer treatment: Emergence from a preclinical study. Pancreas 43(1), 53-63 (2014).
120. Zeng R, Zeng L, Chen Y et al. Triptolide-induced apoptosis by inactivating nuclear factor-kappa B apoptotic pathway in multiple myeloma in vitro. J. Huazhong. Univ. Sci. Technol. Med. Sci. 31(4), 446-451 (2011).
121. Berkovich L, Earon G, Ron I, Rimmon A, Vexler A, Lev-Ari S. Moringa Oleifera aqueous leaf extract down-regulates nuclear factor-kappaB and increases cytotoxic effect of chemotherapy in pancreatic cancer cells. BMC Complement. Altern. Med. 13, 212 (2013).
122. Eldor R, Abel R, Sever D et al. Inhibition of nuclear factor-kappaB activation in pancreatic beta-cells has a protective effect on allogeneic pancreatic islet graft survival. PLoS One 8(2), e56924 (2013).
123. Wang Y, Zhu Y, Gao L et al. Formononetin attenuates IL-1beta-induced apoptosis and NF-kappaB activation in INS-1 cells. Molecules 17(9), 10052-10064 (2012).
124. Ogasawara A, Simizu S, Ito A et al. Inhibition of NO-induced beta-cell death by novel NF-kappaB inhibitor (-)-DHMEQ via activation of Nrf2-ARE pathway. Biochem. Biophys. Res. Commun. 433(2), 181-187 (2013).
125. Radhakrishnan P, Bryant VC, Blowers EC et al. Targeting the NF-kappaB and mTOR pathways with a quinoxaline urea analog that inhibits IKKbeta for pancreas cancer therapy. Clin. Cancer Res. 19(8), 2025-2035 (2013).
126. Minde DP, Anvarian Z, Rudiger SG, Maurice MM. Messing up disorder: How do missense mutations in the tumor suppressor protein APC lead to cancer?. Mol. Cancer 10, 101 (2011).
127. Prise KM, Schettino G, Folkard M, Held KD. New insights on cell death from radiation exposure. Lancet Oncol. 6(7), 520-528 (2005).
128. Arazi L, Cooks T, Schmidt M, Keisari Y, Kelson I. Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters. Phys. Med. Biol. 52(16), 5025-5042 (2007).
129. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leukocyte adhesion molecule 1: An inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243(4895), 1160-1165 (1989).
130. Hallahan DE, Vokes EE, Rubin SJ et al. Phase I dose-escalation study of tumor necrosis factor-Alpha and concomitant radiation therapy. Cancer J. Sci. Am. 1(3), 204-209 (1995).
131. Houenou LJ, D'costa AP, Li L et al. Pigment epithelium-derived factor promotes the survival and differentiation of developing spinal motor neurons. J. Comp. Neurol. 412(3), 506-514 (1999).
132. Uehara H, Miyamoto M, Kato K et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res. 64(10), 3533-3537 (2004).
133. Zhang X, Xu J, Lawler J, Terwilliger E, Parangi S. Adeno-Associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin. Cancer Res. 13(13), 3968-3976 (2007).
134. Hanna N, Ohana P, Konikoff FM et al. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther. 19(6), 374-381 (2012).
135. Matouk IJ, Degroot N, Mezan S et al. The H19 non-coding RNA is essential for human tumor growth. PLoS One 2(9), e845 (2007).
136. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31, 705-742 (2013).
137. Rosemurgy A, Luzardo G, Cooper J et al. 32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: A randomized trial. J. Gastrointest. Surg. 12(4), 682-688 (2008).
138. Lee I. Enhanced tumor targeting by an intratumoral injection of colloidal chromic 32P in two human tumors (AsPC-1 pancreas and Ls174T colon) in nude mice. J. Surg. Oncol. 70(3), 161-166 (1999).
139. Hecht JR, Bedford R, Abbruzzese JL et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 9(2), 555-561 (2003).
140. Block A, Chen SH, Kosai K, Finegold M, Woo SL. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors. Pancreas 15(1), 25-34 (1997).
141. Yang L, Hwang R, Pandit L, Gordon EM, Anderson WF, Parekh D. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann. Surg. 224(3), 405-414 (1996). discussion 414-407
142. Kumar M, Liu ZR, Thapa L, Wang DY, Tian R, Qin RY. Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by somatostatin receptor subtype 2. Pancreas 29(2), 141-151 (2004).
143. Garbe AI, Vermeer B, Gamrekelashvili J et al. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res. 66(1), 508-516 (2006).
144. Schmidt J, Mocevicius P, Werner J, Ryschich E. The role of the tumor endothelium in leukocyte recruitment in pancreatic cancer. Surgery 152(3 Suppl. 1), S89-S94 (2012).
145. Heller A, Zornig I, Muller T et al. Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer. Cancer Immunol. Immunother. 59(9), 1389-1400 (2010).
146. Raut CP, Boucher Y, Duda DG et al. Effects of sorafenib on intra-Tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One 7(2), e26331 (2012).
147. Paley EL, Paley DE, Merkulova-Rainon T, Subbarayan PR. Hypoxia signature of splice forms of tryptophanyl-TRNA synthetase marks pancreatic cancer cells with distinct metastatic abilities. Pancreas 40(7), 1043-1056 (2011).
148. Turpaev KT, Zakhariev VM, Sokolova IV et al. Alternative processing of the tryptophanyl-TRNA synthetase mRNA from interferon-Treated human cells. Eur. J. Biochem. 240(3), 732-737 (1996).
149. Govindarajan S, Sivakumar J, Garimidi P et al. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-Affibody bioconjugate. Biomaterials 33(8), 2570-2582 (2012).
150. Gopal V, Guruprasad K. Structure prediction and validation of an affibody engineered for cell-specific nucleic acid targeting. Syst. Synth. Biol. 4(4), 293-297 (2010).
151. Cunha-Filho MS, Alvarez-Lorenzo C, Martinez-Pacheco R, Landin M. Temperature-sensitive gels for intratumoral delivery of beta-lapachone: Effect of cyclodextrins and ethanol. Sci. World J. 126723 (2012).(2012).
152. Luo X, Xie C, Wang H, Liu C, Yan S, Li X. Antitumor activities of emulsion electrospun fibers with core loading of hydroxycamptothecin via intratumoral implantation. Int. J. Pharm. 425(1-2), 19-28 (2012).
153. Zheng X, Zhou F, Wu B, Chen WR, Xing D. Enhanced tumor treatment using biofunctional indocyanine green-containing nanostructure by intratumoral or intravenous injection. Mol. Pharm. 9(3), 514-522 (2012).
154. Yallapu MM, Ebeling MC, Khan S et al. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol. Cancer Ther. 12(8), 1471-1480 (2013).
155. Lubutti SK. New horizons in cancer gene therapy. Cancer Gene Therapy.21(1), 1 (2014).
156. Ji S, Xu J, Zhang B et al. RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. Cancer Biol. Ther. 13(4), 206-215 (2012).